Phase 4 N=28 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
Verruca, Warts
Primary: Size of Verrucae (Warts) — 2.333; 3.889 millimeters — p=0.383
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
N/A N=35 Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Atopic Dermatitis · Ichthyosis Vulgaris
Primary: Heterozygous for Filaggrin (FLG) Null Mutations — 1; 4 participants
Phase 4 N=23 Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
Acne Vulgaris
Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
Phase 2 N=587 Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Acne Vulgaris
Primary: Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12 — -16.8; -18.1; -18.9; -18.8 Lesion count — p=0.692
Phase 2 N=39 Candin Safety & Efficacy Study for the Treatment of Warts
Warts · Human Papilloma Virus
Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
Phase 2 N=169 Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Warts
Primary: Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit — 16; 29; 31; 29 Participants — p=0.0329
Phase 3 N=491 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Cutaneous Common Warts
Primary: The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Phase 2 N=183 A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Common Warts
Primary: Complete Resolution of All Treated Warts by or at Week 12 — 2; 5; 2; 3 Participants
Phase 3 N=484 A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Cutaneous Common Warts
Primary: Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Phase 3 N=1,239 Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
Psoriasis Vulgaris
Primary: Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind…
Phase 2 N=363 A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
Acne Vulgaris
Primary: Investigator's Global Assessment (IGA) "Success" - Week 12 — 5; 3; 2; 6 Participants
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
Phase 4 N=221 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Percentage Change From Baseline (Day 1) of Inflammatory Lesion (IL) Count at Week 4 - Superiority Analysis — -51.9; -38.1 Percent change — p=0.0004
Phase 4 N=20 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants